KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 120 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 1.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $23,449,127 | +17.3% | 1,990,588 | +18.1% | 0.00% | – |
| Q1 2024 | $19,985,440 | -8.4% | 1,685,113 | -5.4% | 0.00% | – |
| Q4 2023 | $21,822,382 | +30.8% | 1,781,419 | +2.8% | 0.00% | – |
| Q3 2023 | $16,683,869 | +17.3% | 1,732,489 | +9.6% | 0.00% | – |
| Q2 2023 | $14,226,129 | +14.4% | 1,580,681 | -0.1% | 0.00% | – |
| Q1 2023 | $12,438,654 | +59.6% | 1,582,526 | +37.3% | 0.00% | – |
| Q4 2022 | $7,792,070 | -53.3% | 1,152,673 | +0.2% | 0.00% | – |
| Q3 2022 | $16,684,000 | +46.5% | 1,149,861 | -0.6% | 0.00% | – |
| Q2 2022 | $11,386,000 | -33.8% | 1,157,158 | -0.8% | 0.00% | – |
| Q1 2022 | $17,196,000 | +14.2% | 1,166,652 | +2.5% | 0.00% | – |
| Q4 2021 | $15,062,000 | -27.3% | 1,138,484 | -4.1% | 0.00% | -100.0% |
| Q3 2021 | $20,709,000 | -10.4% | 1,186,747 | +23.1% | 0.00% | 0.0% |
| Q2 2021 | $23,108,000 | -3.2% | 964,419 | +3.8% | 0.00% | 0.0% |
| Q1 2021 | $23,878,000 | +121.6% | 929,481 | +63.8% | 0.00% | – |
| Q4 2020 | $10,777,000 | +53.2% | 567,548 | +1.6% | 0.00% | – |
| Q3 2020 | $7,036,000 | +4.0% | 558,853 | -0.1% | 0.00% | – |
| Q2 2020 | $6,768,000 | +57.9% | 559,332 | -0.2% | 0.00% | – |
| Q1 2020 | $4,286,000 | -56.2% | 560,193 | +1.8% | 0.00% | – |
| Q4 2019 | $9,795,000 | +55.2% | 550,019 | +1.1% | 0.00% | – |
| Q3 2019 | $6,312,000 | -46.0% | 544,048 | +3.1% | 0.00% | – |
| Q2 2019 | $11,692,000 | +14.3% | 527,829 | +47.7% | 0.00% | – |
| Q1 2019 | $10,228,000 | +51.9% | 357,390 | +4.9% | 0.00% | – |
| Q4 2018 | $6,732,000 | +2.7% | 340,843 | +14.9% | 0.00% | – |
| Q3 2018 | $6,558,000 | +587.4% | 296,581 | +152.4% | 0.00% | – |
| Q2 2018 | $954,000 | -14.1% | 117,489 | +0.3% | 0.00% | – |
| Q1 2018 | $1,110,000 | -3.8% | 117,095 | -1.1% | 0.00% | – |
| Q4 2017 | $1,154,000 | -13.2% | 118,338 | -40.7% | 0.00% | – |
| Q3 2017 | $1,330,000 | +2.1% | 199,618 | +10.4% | 0.00% | – |
| Q2 2017 | $1,303,000 | -7.7% | 180,872 | +0.1% | 0.00% | – |
| Q1 2017 | $1,412,000 | +407.9% | 180,772 | +360.0% | 0.00% | – |
| Q4 2016 | $278,000 | – | 39,296 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $13,155,000 | 11.03% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $2,974,000 | 3.14% |
| Vivo Capital, LLC | 1,476,796 | $11,297,000 | 1.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 227,433 | $1,731,000 | 0.79% |
| DAFNA Capital Management LLC | 234,952 | $1,797,000 | 0.75% |
| Samsara BioCapital, LLC | 168,174 | $1,287,000 | 0.74% |
| Ghost Tree Capital, LLC | 350,000 | $2,678,000 | 0.71% |
| Ikarian Capital, LLC | 946,605 | $7,242,000 | 0.54% |
| Opaleye Management Inc. | 225,000 | $1,721,000 | 0.46% |
| Eventide Asset Management | 1,680,000 | $12,852,000 | 0.42% |